Ebola Vaccine Trial in Guinea
ISPM and CTU Bern will participate in a trial to evaluate the effectiveness of ring vaccination to control the current outbreak in Guinea, West Africa. We are urgently looking for staff to support this trial in Guinea and Bern.
The number of Ebola Virus Disease cases continues to fluctuate in Guinea, with no identifiable downward trend. At the same time Phase 1 studies of vaccine candidates have produced promising immunogenicity and safety results. These vaccines now need to be evaluated further for safety, efficacy and effectiveness.
Matthias Egger, Sven Trelle and Stefanie Hossmann from ISPM and CTU Bern have contributed to the design of a ring vaccination trial in Guinea, under the auspices of the World Health Organization. The trial will be performed as a randomized phase 3 trial to evaluate the efficacy, effectiveness and safety of one dose of either cAd3 or rVSV vaccine in the prevention of EVD when implemented as ring vaccination.
ISPM and CTU Bern will be responsible for the data management and statistical analysis, together with colleagues at WHO, the Norwegian Public Health Institute, the London School of Hygiene and Tropical Medicine and the University of Florida. The trial will be implemented by Médecins Sans Frontières who have been supporting the Ebola response in Guinea since the start of the epidemic.
We are urgently looking for data managers, trial coordinators, statisticians and IT specialists to support this very urgent study. Please contact Stefanie Hossmann if you are interested.